company background image
CASI

CASI Pharmaceuticals NasdaqCM:CASI Stock Report

Last Price

US$2.72

Market Cap

US$37.0m

7D

-5.9%

1Y

-76.6%

Updated

05 Oct, 2022

Data

Company Financials +
CASI fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CASI Stock Overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally.

CASI Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CASI Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.72
52 Week HighUS$12.30
52 Week LowUS$2.24
Beta0.44
1 Month Change-27.85%
3 Month Change-4.90%
1 Year Change-76.55%
3 Year Change-91.20%
5 Year Change-91.71%
Change since IPO-99.84%

Recent News & Updates

Sep 23

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Casi Pharmaceuticals (NASDAQ:CASI) is selling its equity interest of 12.0098% in Juventas Biotechnology (Tianjin) to Shenzhen Jiadao Gongcheng Equity Investment Fund for RMB240.87M (~$34.03M). Casi's unit Casi Biopharmaceuticals (Wuxi) signed the equity transfer agreement with Jiadao under which one payment will be made after signing and the second after the equity transaction is completed, the Rockville, Md.-based company said in a Sept. 23 press release. "The completion of the equity transfer transaction will strengthen CASI's balance sheet by providing CASI with sufficient cash to operate until, at least, the end of 2023," said Casi's Chairman and CEO Wei-Wu He. The CEO added that Casi expects Juventas to file an application an application to the Chinese drug regulator seeking approval of CNCT-19 for  B-cell acute lymphoblastic leukemia. "CASI and Juventas will continue to maintain a working partnership, focusing on product launch and co-marketing for CNCT-19," the CEO commented.

Aug 11

CASI Pharmaceuticals Q2 2022 Earnings Preview

CASI Pharmaceuticals (NASDAQ:CASI) is scheduled to announce Q2 earnings results on Friday, August 12th, before market open. The consensus EPS Estimate is -$0.61 (-1120.0% Y/Y) and the consensus Revenue Estimate is $7.87M (+9.9% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

Shareholder Returns

CASIUS BiotechsUS Market
7D-5.9%5.1%4.4%
1Y-76.6%-20.8%-18.2%

Return vs Industry: CASI underperformed the US Biotechs industry which returned -20.8% over the past year.

Return vs Market: CASI underperformed the US Market which returned -18.2% over the past year.

Price Volatility

Is CASI's price volatile compared to industry and market?
CASI volatility
CASI Average Weekly Movement16.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CASI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: CASI's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1991176Wei-Wu Hehttps://www.casipharmaceuticals.com

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome.

CASI Pharmaceuticals, Inc. Fundamentals Summary

How do CASI Pharmaceuticals's earnings and revenue compare to its market cap?
CASI fundamental statistics
Market CapUS$37.01m
Earnings (TTM)-US$32.10m
Revenue (TTM)US$34.91m

1.1x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CASI income statement (TTM)
RevenueUS$34.91m
Cost of RevenueUS$14.53m
Gross ProfitUS$20.38m
Other ExpensesUS$52.48m
Earnings-US$32.10m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.36
Gross Margin58.39%
Net Profit Margin-91.97%
Debt/Equity Ratio1.1%

How did CASI perform over the long term?

See historical performance and comparison